Introduction
For millions of years, viruses have been co-evolving with their hosts. During this process, they have had to deal with the most complex aspects of host physiology, often mimicking, hijacking or sabotaging host biological processes to their benefit. In this respect, many viruses have evolved strategies to deregulate the host immune response in order to avoid immune surveillance and elimination from the host. These strategies include mechanisms to deregulate the host cytokine network.
The IL-10 family of cytokines and the related IFN family of cytokines form the larger class II cytokine family (Ouyang et al., 2011) . The IL-10 family of cytokines can be categorized into three subgroups, based primarily on biological functions: (i) IL-10 itself, (ii) the IL-20 subfamily cytokines composed of and (iii) the type III IFN group (also called IFN-ls) (Ouyang et al., 2011; Pestka et al., 2004) . IL-10 is a pleiotropic cytokine, with both immunostimulatory and immunosuppressive properties (Moore et al., 2001) . However, its key features relate mainly to its capacity to exert potent effects in the latter category via several mechanisms. Various viruses have been shown to upregulate the expression of cellular IL-10 (cIL-10) with, in some cases, an enhancement of infection by suppression of immune functions (Brady et al., 2003; Brockman et al., 2009; Díaz-San Segundo et al., 2009; Yu et al., 2008) . These studies suggest that cIL-10 expression Further supporting this conclusion, several viruses encode orthologues of cIL-10, called viral IL-10s (vIL-10s), that appear to have been acquired by viruses on multiple independent occasions from their host during evolution. This review is devoted to these virokines. Various aspects of vIL-10s are described, including their genetic organization, protein structure, origin, evolution, biological properties in vitro and in vivo, and potential in applied research.
Discovery of vIL-10s
Cloning and sequencing of human and mouse IL-10s led to the identification of the first vIL-10 orthologue. It was discovered that the uncharacterized ORF BCRF1 of Epstein-Barr virus (EBV; human herpesvirus 4) encoded a protein that exhibited high sequence identity (92.3 %) with human IL-10 . Subsequently, various studies documented that this protein possessed some of the specific biological activities of cIL-10 and it was therefore concluded that BCRF1 encoded a functional viral orthologue of human IL-10 (Hsu et al., 1990; Niiro et al., 1992) . Following this, the sequencing of an increasing number of viral genomes has revealed a growing list of vIL-10s. To date, vIL-10 orthologues have been reported for 12 members of the family Herpesviridae, two members of the family Alloherpesviridae and seven members of the family Poxviridae (Table 1) .
Genetic structure of IL-10 orthologues
The basic structure of the human IL-10 gene consists of five protein-coding exons (I-V) encoding a spliced mRNA of 1629 bp including untranslated regions (UTRs) ( Fig. 1 ) (Moore et al., 2001; Sabat, 2010) . The first part of exon I and the last part of exon V encode the 59-and 39-UTRs, respectively. The remaining parts of exons I and V, together with exons II-IV, encode a single protein of 178 aa. The sizes of the exons are largely conserved among animal species. In contrast, the sizes of the introns show greater variation and may be up to 1 kbp in length.
The general intron-exon structure of cIL-10 is only found in ovine herpesvirus 2 (OvHV-2), although the introns are considerably shorter than those of its natural host, i.e. sheep (Jayawardane et al., 2008) . For the other vIL-10s, variations are observed in the number and positions of introns ( Holmes, 2004) . The latter process requires reverse transcriptase activity, most likely derived from retrovirus co-infection of the host cell (Brunovskis & Kung, 1995; Isfort et al., 1992) . Direct gene capture from the host genome results in preservation of the original cellular intron-exon structure, as in OvHV-2 (Jayawardane et al., 2008) . Subsequent selective pressure could result in successive shortening or even loss of one or more introns, as exemplified by the vIL-10 variants that do not contain the full subset of exons. The intronless vIL-10 genes most likely represent gene capture via reverse transcription of cellular mRNA, but could theoretically also represent a final stage of intron loss from a gene captured originally from genomic DNA. The fact that all poxvirus vIL-10 genes are intronless probably reflects the cytoplasmic replication cycle of poxviruses, which may exclude the possibility of direct capture of host genes via recombination in the nucleus (Bratke & McLysaght, 2008) .
Origin and evolution of vIL-10s
Bioinformatical analyses were performed in the context of the present review: (i) to identify all viral sequences encoding IL-10 orthologues that are available in the public databases and (ii) to determine whether these sequences are true vIL-10s or orthologues of cellular genes related to cIL-10. Methods and sequences used for these analyses are provided as supplementary material S1 (available in JGV Online). The viral sequences listed in Table 1 and the 134R gene encoded by Yaba-like disease virus (Lee et al., 2001) were previously detected as viral sequences related to cIL-10. Among the sequences listed in Table 1 , a sequence highly homologous to EBV vIL-10 was found in the bonobo genome sequence. We assumed that this resulted from the sequencing of a contaminating herpesvirus, hereafter called bonobo herpesvirus (bonobo-HV). The rationale that led to this conclusion is described in supplementary material S2. Fig. 2 presents the phylogenetic analysis of all the detected viral sequences, together with cIL-10 orthologues and representative members of the wider IL-10 family of cytokines. Fig. 2 demonstrates that the 134R protein from Yaba-like disease virus is most closely related to IL-24 proteins, although its exact position in the phylogenetic tree is not well defined in terms of bootstrap values. Further supporting the conclusion that the 134R protein is not an IL-10 orthologue, Bartlett et al. (2004) demonstrated that it signalled via the IL-20 receptor complex. Thus, it is clear that the 134R protein is not a true vIL-10 and it was therefore removed from further analyses.
Many of the vIL-10 genes are situated in orthologous locations in viral genomes, referred to here as positional orthology. Given that it is unlikely that gene capture would integrate cIL-10 into the same viral genome location on more than one occasion, positional orthology is assumed to represent ancient viral capture events in ancestral viruses. Four positionally orthologous sets of vIL-10 can be defined in the genera Cytomegalovirus, Lymphocryptovirus, Parapoxvirus and Capripoxvirus. All four of these sets cluster together in the Bayesian tree for vIL-10s and the cIL-10s of a selection of their hosts ( Fig. 3 ). Based on Fig. 3 , it can be concluded that the positionally orthologous clade of vIL-10s of the genus Lymphocryptovirus [EBV/baboon lymphocryptovirus (BaLCV)/rhesus lymphocryptovirus (RhLCV)/ bonobo-HV] is a nearest-neighbour to a clade comprising the corresponding ape cIL-10s. This capture of cIL-10 by an ancestral lymphocryptovirus must therefore have taken place after the divergence of Old World primates from New World primates 42 million years ago, since marmoset IL-10 is an outlier to both members of the genus Lymphocryptovirus and Old World primate lineages. The minimum date for this gene capture is more difficult to estimate, as the resolution of the tree does not make it possible to distinguish between it having occurred prior to the human-gorilla divergence, at 9 million years ago, or the ape-monkey divergence, at 29 million years ago. In the vIL-10s of members of the genus Cytomegalovirus [human cytomegalovirus (HCMV) and others in that clade], an ancient capture event can again be inferred because of positional orthology. This event would have to have taken place at least 42 million years ago, which is when the Old and New World monkey lineages diverged. Apart from HCMV cmvIL-10, the vIL-10s in the genus Cytomegalovirus clade have the same branching pattern as IL-10s of the hosts. The best explanation for the anomalous position of HCMV cmvIL-10 in this clade is that there has been particular selective pressure on HCMV. In this context, it is notable that the nearest relative of HCMV, chimpanzee CMV (CCMV), lacks a vIL-10 gene, suggesting that some evolutionary pressure in the common ancestor of humans and chimpanzees resulted in the loss of this gene from CCMV and also its extensive modification in HCMV. Concerning CCMV, as there is only one reported sequence, even if unlikely, one cannot exclude the possibility that this gene has been lost during viral replication in cell culture. For the positionally orthologous vIL-10s of members of the genus Parapoxvirus [orf virus (ORFV)/bovine papular stomatitis virus (BPSV)/pseudocowpox virus (PCPV)], it is apparent that the ancestor of these proteins was captured prior to divergence of the sheep and goat lineages 7.3 million years ago. However, it is more difficult to specify a maximum date for this gene capture event as the relationships of parapoxvirus vIL-10s to bovine and cervine IL-10 are poorly resolved.
The Bayesian tree does not help with the assessment of the vIL-10s of the fish viruses anguillid herpesvirus 1 (AngHV-1) and cyprinid herpesvirus 3 (CyHV-3), nor of OvHV-2, canarypox virus or the capripoxviruses [lumpy skin disease virus (LSDV)/sheeppox virus (SPV)/goatpox virus (GPV)]. However, it seems unlikely that any of these vIL-10s represents a recent capture from the host. The capripoxvirus vIL-10s constitute a clade, but its point of divergence from the host sequences cannot be pinpointed in the same way as for the parapoxviruses. The only obvious example of a recent gene capture event for the origin of a vIL-10 is in equid herpesvirus 2 (EHV-2).
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Overall, based on positional orthology, amino acid sequence comparisons and the presumed modes of gene capture, at least eight, and possibly nine (assuming that AngHV-1 and CyHV-3 vIL-10s represent independent acquisitions), different viral cIL-10 capture events can be discriminated.
Protein structure of IL-10 orthologues
Amino acid sequence conservation is rather low among the three subgroups of the IL-10 family of cytokines (IL-10, IL-20 subfamily cytokines and type III IFN group) (Zdanov, 2004) . In particular, type III IFNs are closer to type I IFNs than to the IL-10. For example, the amino acid sequence of IFN-l3 (which belongs to the type III IFN group) is more similar to that of type I IFNs (33 % similarity) than to the IL-10 (23 % similarity) (Gad et al., 2009 ). Moreover, induction of gene expression and biological activities of type III IFNs are more similar to those described for type I IFNs (Ouyang et al., 2011) . However, IFN-l3 is structurally more closely related to the IL-10 family of cytokines, especially IL-22 (Gad et al., 2009) , and has been shown to signal through the same IL-10R2 chain (Ouyang et al., 2011) .
cIL-10s are well conserved among species (Lockridge et al., 2000; Moore et al., 2001) . Indeed, the high level of conservation among cIL-10s contrasts with the variable (25-97.2 %), and frequently low levels of identity observed between vIL-10s and their respective host IL-10s (Table 1) . However, as illustrated in Fig. 1 (colour code) , the percentage of conservation is not distributed uniformly along vIL-10s. It is generally higher for amino acid regions corresponding to the regions encoded by cIL-10 exons 1 (with the exception of the signal peptide region), 3 and 5. Table 1 . Boxes and horizontal lines represent exons and introns, respectively. They are drawn to scale. The 59-and 39-UTRs of human IL-10 are not shown. The homology existing between each human IL-10 exon and vIL-10s was investigated at the level of amino acid sequences using the accession numbers listed in Table 1 and the FASTA sequence comparison program (http://fasta.bioch.virginia.edu/fasta_www2/index.cgi) using default settings. Regions of vIL-10 DNA sequences encoding amino acid sequences homologous to human IL-10 protein domains encoded by each exon are drawn to scale using the following colour code: exon 1: red, exon 2: yellow, exon 3: blue, exon 4: green, exon 5: orange. Regions of vIL-10s for which no homology could be detected are presented in grey. HCMV cmvIL-10 and LAcmvIL-10 represent transcripts of the HCMV UL111A gene expressed during lytic and latent infections, respectively. The former retains the structure of the gene consisting of three exons and two introns, and the latter retains only the first intron, resulting in an in-frame stop codon 12 codons after the second exon.
Viral IL-10s
Independent of the level of identity between vIL-10s and cIL-10s, the former share many features with the latter. (i) cIL-10s and vIL-10s are secreted proteins. They are synthesized as precursors expressing a 17-33 residue hydrophobic signal peptide at the N terminus (Table 1) . This peptide is cleaved during secretion (Kotenko & Pestka, 2001) . (ii) All cIL-10s encode two family signature motifs: (Pinto et al., 2007; Zhang et al., 2005) . These motifs, which are essential for the structure and function of cIL-10s, are conserved to a large extent in vIL-10s. (iii) Despite the variable sequence homology observed between cIL-10s and vIL-10s at the amino acid sequence level, their determined or predicted structures are conserved highly (Fig. 4) . The crystal structure of human IL-10 has been determined as a free ligand (Walter & Nagabhushan, 1995; Yoon et al., 2006; Zdanov et al., 1995 Zdanov et al., , 1996 and as a binary complex bound to its soluble receptor (Josephson et al., 2001) . These studies demonstrated that cIL-10, like all members of the IL-10 family of class II cytokines, possesses a characteristic a-helical fold consisting of six helices (A-F) and connecting loops ( Fig. 4a ). It is secreted as a domain-swapped homodimer in which two adjacent non-covalently bound peptides exchange helices E and F to form a twofold symmetrical, V-shaped reciprocal dimer (Zdanov et al., 1995) . The crystal structures of EBV vIL-10 and HCMV cmvIL-10 have been determined (Jones et al., 2002; Yoon et al., 2005; Zdanov et al., 1997) (Fig. 4c, d) , and were proved to be similar to that of human IL-10 with the exception that HCMV cmvIL-10 lacks helix B (Jones et al., 2002) . Using the receptor-bound structure of human IL-10 as a template (Josephson et al., 2001) , the three-dimensional protein structures of the CyHV-3 and AngHV-1 vIL-10s and the cIL-10s of their respective host were predicted (van Beurden et al., 2011) ( Fig. 4e , f). These in silico analyses suggested that the vIL-10s encoded by these two alloherpesviruses share the conserved structure described for cIL-10.
Transcriptomic and proteomic expression of vIL-10 genes Expression of vIL-10 genes has been studied at the RNA and protein levels. Depending on the viral species, genes encoding vIL-10s have been shown to be transcribed during in vitro replication at early times for rhesus CMV (RhCMV) (Lockridge et al., 2000) , HCMV LAcmvIL-10 (Jenkins et al., 2008a) and CyHV-3 (Ilouze et al., 2012) , at early/late times for CyHV-3 (Ouyang et al., 2013) or at late times for EBV (Hudson et al., 1985; Miyazaki et al., 1993; Touitou et al., 1996) , HCMV cmvIL-10 (Chang et al., 2004) and AngHV-1 (van Beurden et al., 2013) .
The HCMV UL111A gene encodes a vIL-10, and has been shown to generate different transcripts during lytic and latent infections as a consequence of differential splicing (Jenkins et al., 2004; Kotenko et al., 2000) . HCMV cmvIL-10 is expressed during the productive phase of infection (Chang et al., 2004; Spencer et al., 2002) , whereas LAcmvIL-10 has been reported to be expressed during both latent (Jenkins et al., 2004) and productive infections (Jenkins et al., 2008a) . Both transcripts share the same initiation codon. However, as a result of the lack of splicing of the second intron, LAcmvIL-10 retains only the first two exons present in the lytic transcript (cmvIL-10), resulting in an in-frame stop codon 12 codons after the second exon. As a consequence, LAcmvIL-10 encodes a truncated protein of 139 residues that shares its first 127 residues with the longer protein encoded by the cmvIL-10 transcript (Jenkins et al., 2004) . Also, Lin et al. (2008) described five cmvIL-10 isoforms resulting from alternative splicing during in vitro replication of HCMV.
EBV BCRF1 was classified as a late gene (Hudson et al., 1985) , although it is expressed in B-cells relatively early after infection (Jochum et al., 2012; Miyazaki et al., 1993) . There is no evidence for BCRF1 transcription and protein secretion during in vitro latency. However, in in vivo studies, Xu et al. (2001) detected expression of BCRF1 in latently infected patients with NK/T-cell lymphoma (Xu et al., 2001) .
Expression of CyHV-3 ORF134, which encodes a vIL-10, has been detected in vivo during acute primary infection and subsequent reactivation phases. Expression during persistent infection at restrictive temperature was low or below the detection level (Sunarto et al., 2012) .
Secretion of vIL-10 in the extracellular compartment has been demonstrated for several viruses in cell culture: RhCMV (Lockridge et al., 2000) , HCMV (cmvIL-10) (Chang et al., 2004) , EBV (Touitou et al., 1996) and CyHV-3 (Ouyang et al., 2013) . In vivo secretion has been demonstrated for RhCMV (Lockridge et al., 2000) . 
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The effect of vIL-10 on virus growth in vitro has been studied using recombinant strains containing knockout or nonsense mutations. For all viruses tested, vIL-10 genes were shown to be non-essential for growth of HCMV (Dunn et al., 2003) , RhCMV (Chang & Barry, 2010) 
Viral IL-10s
Ligand-receptor complexes formed by IL-10 orthologues cIL-10 acts through a specific cell surface receptor (IL-10R) complex, which is composed of two different class II cytokine receptor family (CRF2) subunits: IL-10R1 and IL-10R2 (Moore et al., 2001; Zdanov, 2004) . IL-10R1 is the highaffinity receptor subunit and is expressed mainly on immune cells (Liu et al., 1994) . cIL-10 first binds to IL-10R1, which leads to changes in its conformation and subsequent association with the low-affinity receptor subunit IL-10R2 (Yoon et al., 2006) . In contrast to IL-10R1, IL-10R2 has a broader expression pattern, being expressed on most immune and non-immune cells. However, IL-10R2 is unable to bind cIL-10 in the absence of IL-10R1 (Kotenko et al., 1997; Wolk et al., 2005) . Binding of cIL-10 to the IL-10R complex activates a signalling pathway, which mainly acts through receptor-associated Janus kinase 1 (Jak1, associated with IL-10R1), tyrosine kinase 2 (Tyk2, associated with IL-10R2) and signal transduction and transcription (STAT) factors, leading to initiation of transcription of the appropriate genes (Sabat et al., 2010) .
HCMV cmvIL-10 and EBV vIL-10 have been shown to bind to and signal through human IL-10R1 (Jones et al., 2002; Yoon et al., 2005) . The regions of the surfaces of the human IL-10 and vIL-10 variants that make contact with the receptor are essentially the same. The binding affinity of HCMV cmvIL-10 (which exhibits only 27 % sequence similarity with human IL-10) to soluble IL-10R1 (sIL-10R1) is essentially similar to that of human IL-10 (Jones et al., 2002) . Furthermore, HCMV cmvIL-10 induces phosphorylation of the transcription factor STAT3 in monocytes, indicating its ability to bind and signal through human IL-10R in a manner comparable to that of human IL-10 (Jenkins et al., 2008b) . The same authors blocked the ability of cmvIL-10 to downregulate MHC class II expression on monocytes by using neutralizing antibodies raised against human IL-10R (Jenkins et al., 2008b) . None of the five cmvIL-10 isoforms resulting from alternative splicing during in vitro replication of HCMV induced phosphorylation of STAT3 despite being able to bind to human IL-10R (Lin et al., 2008) . In contrast to cmvIL-10, LAcmvIL-10 does not induce STAT3 phosphorylation and retains the ability to reduce MHC class II expression on monocytes in the presence of neutralizing antibodies raised against human IL-10R (Jenkins et al., 2008b) . These results suggest that LAcmvIL-10 does not bind to human IL-10R but acts through another receptor, or binds to human IL-10R, but in a different way as compared with cmvIL-10 and human IL-10. These variations most probably resulted from the fact that LAcmvIL-10 is a truncated protein that lacks C-terminal helices E and F. As a consequence, LAcmvIL-10 lacks many of the immunosuppressive functions (see below) that are known for cmvIL-10 (Jenkins et al., 2008b) .
The most prominent structural difference between human IL-10 and HCMV cmvIL-10 bound to sIL-10R1 is the~40 u difference in interdomain angle, which forces a reorganization of the IL-10R1 subunits in the putative cell surface complex (Jones et al., 2002) . The binding affinity of EBV vIL-10 (which has 92 % sequence identity to human IL-10) to cell surface IL-10R1 is~1000-fold lower than that of human IL-10 (Liu et al., 1997) . This difference in receptorbinding affinity is thought to be caused by subtle changes in the conformation and dynamics of two loop structures and the interdomain angle (Yoon et al., 2005) , as well as by single amino acid substitutions (Ding et al., 2000) .
As the crystal structures of human IL-10 and EBV vIL-10 are very similar, the observed functional differences P. Ouyang and others (described below) have been attributed to differences in binding affinity (Ding et al., 2001; Liu et al., 1997) . Recently, the biological effect induced by CyHV-3 vIL-10 in zebrafish embryos was shown to be abrogated by downregulation of IL-10R1 expression using a specific morpholino, suggesting that CyHV-3 vIL-10 also functions through IL-10R1 (Sunarto et al., 2012) .
Biological activities of IL-10 orthologues
Biological activities of cIL-10 cIL-10 was first described as cytokine synthesis inhibitory factor (CSIF), an immune mediator that is produced by T helper T h 2 cell clones, and has inhibitory effects on the synthesis of IL-2 and IFN-c by T h 1 cell clones (Fiorentino et al., 1989) . Today, it is known that many different myeloid and lymphoid cells have the ability to produce IL-10 (Couper et al., 2008; Mosser & Zhang, 2008; Sabat et al., 2010) and that infection by a single pathogen species induces secretion of cIL-10 by more than one cell population, depending on the type of pathogen, the infected tissue and the time point in the immune response (Sabat et al., 2010) . cIL-10 is a type II pleiotropic cytokine with both immunostimulatory and immunosuppressive properties (Moore et al., 2001) . However, the key features of this cytokine relate to its capacity to exert potent immunosuppressive functions on several immune cell types (Moore et al., 1993) . It shows a clear, direct immunosuppressive effect on activated monocytes/macrophages, both by inhibition of the release of pro-inflammatory mediators [TNF-a, IL-1b, IL-6, IL-8, granulocyte colony-stimulating factor (G-CSF) and granulocyte/macrophage colonystimulating factor (GM-CSF)] (de Waal Malefyt et al., 1991a; Fiorentino et al., 1991) and by enhancing the release of anti-inflammatory mediators (such as IL-1 receptor antagonist and soluble TNF-a receptor) (Hart et al., 1996; Jenkins et al., 1994) . Additionally, cIL-10 inhibits antigen presentation by downregulation of the expression of MHC class I, MHC class II and B7-1/B7-2 co-stimulatory molecules (de Waal Malefyt et al., 1991b; Matsuda et al., 1994; Willems et al., 1994) . It also affects dendritic cells (DCs) by preventing their differentiation from monocyte precursors and their maturation (Allavena et al., 1998; Demangel et al., 2002) . Furthermore, cIL-10 hampers the development of T h 1 immunity, both indirectly by inhibiting IL-12 synthesis by antigen-presenting cells, and directly by inhibiting IL-2 and IFN-c production by T h 1 cells (D'Andrea et al., 1993; Fiorentino et al., 1991) . Moreover, cIL-10 acts directly on T h 2 cells, and inhibits IL-4 and IL-5 synthesis (Del Prete et al., 1993) . cIL-10 also has an immunosuppressive effect on neutrophilic and eosinophilic granulocytes by preventing the synthesis of lipopolysaccharide (LPS)-induced pro-inflammatory mediators (Cassatella et al., 1993; Takanaski et al., 1994) . Thus, cIL-10 plays a key role in the inhibition of the pro-inflammatory responses. It is thought that the role of this inhibition is to protect tissues from the lesions that could result from exaggerated inflammation (Banchereau et al., 2012) .
Notably, apart from its immunosuppressive role, cIL-10 also shows a stimulatory effect on several types of immune cell. It may prevent apoptosis of B-cells, enhancing their activation and contributing to immunoglobulin class switching (Go et al., 1990; Rousset et al., 1992) . cIL-10 alone or in combination with other cytokines may also have a stimulatory effect on proliferation of, and cytokine production by, certain subsets of cytotoxic T-cells (Rowbottom et al., 1999; Santin et al., 2000) , mast cells (Thompson-Snipes et al., 1991) and NK cells (Cai et al., 1999; Carson et al., 1995) .
Biological activities of vIL-10s
The biological activities of vIL-10s have been studied mainly in vitro using recombinant proteins generated from bacterial or mammalian cell expression systems, supernatants from viral-infected cultures or, to a lesser extent, recombinant vIL-10 knockout viruses. Only a restricted number of studies have addressed the roles of vIL-10s in vivo by comparing WT and vIL-10 knockout viruses. These in vitro and in vivo studies are summarized below. In vitro studies are presented according to the immune process affected by vIL-10s, while in vivo studies are organized by virus species studied.
Biological activities of vIL-10s determined in vitro.
Inhibition of cytokine synthesis and leukocyte proliferation.
The hallmark activity of cIL-10 is the inhibition of cytokine production following pro-inflammatory signals. In vitro studies suggest that this activity is conserved among most viral orthologues. The studies supporting this conclusion are summarized below.
HCMV cmvIL-10 inhibits gene expression and secretion of pro-inflammatory cytokines by LPS-stimulated peripheral blood mononuclear cells (PBMCs), monocytes, monocytederived DCs (MDDCs) and plasmacytoid DC (PDCs) (Avdic et al., 2013; Chang et al., 2004 Chang et al., , 2009 Jenkins et al., 2008b; Nachtwey & Spencer, 2008; Raftery et al., 2004; Spencer, 2007; Spencer et al., 2002) . Similarly, the orthologous RhCMV vIL-10 has been shown to inhibit production of pro-inflammatory cytokines by LPS-stimulated PBMCs and monocytes (Logsdon et al., 2011; Spencer et al., 2002) . In addition, both HCMV cmvIL-10 and RhCMV vIL-10 reduced IFN-c production by phytohaemagglutinin-stimulated human PBMCs, as well as human and rhesus PBMC proliferation (Spencer et al., 2002) . HCMV cmvIL-10 secreted by HCMV-infected cells can directly suppress the synthesis of type I IFNs by PDCs (Chang et al., 2009) , demonstrating that HCMV cmvIL-10 can act in trans, since PDCs are highly resistant to infection by HCMV . HCMV cmvIL-10 has a marked impact on microglial cells, which play a role in host defence against HCMV brain infection. Pretreatment of microglial cells with recombinant HCMV cmvIL-10 prior to stimulation with HCMV significantly decreased the protein level of CXC chemokine ligand 10 (CXCL10), which is known to be involved in the recruitment of activated T lymphocytes in infected tissues (Cheeran et al., 2003) . Very recent studies demonstrated that cmvIL-10 influences monocyte polarization by induction of development of M2 alternatively activated monocytes type c (M2c). The M2c polarization of monocytes by cmvIL-10 resulted in upregulation of the anti-inflammatory enzyme haem oxygenase-1 (HO-1), and this was shown to play an important role in viral IL-10-mediated suppression of proinflammatory cytokines by M2c monocytes (Avdic et al., 2013) . Moreover, M2c monocyte polarization by cmvIL-10 reduces the ability to stimulate CD4 + T-cell activation and proliferation (Avdic et al., 2013) .
In contrast to cmvIL-10, LAcmvIL-10 showed no inhibitory effect on IL-1a, IL-1b, IL-6 or TNF-a expression by LPS-stimulated MDDCs (Jenkins et al., 2008b) . However, in another study, it was shown to inhibit TNF-a production by THP-1 myeloid cells stimulated with LPS . Finally, Avdic et al. (2011) demonstrated significantly higher levels of transcription and secretion of cytokines associated with DC formation, as well as an increase in the proportion of myeloid DCs in CD34 + primary myeloid progenitor cells infected latently with HCMV deleted for the UL111A gene region, compared with parental virus or mock infection (Avdic et al., 2011) .
EBV vIL-10 inhibits pro-inflammatory cytokine production by activated cells of various types (de Waal Malefyt et al., 1991a; Hsu et al., 1990; Jochum et al., 2012; Salek-Ardakani et al., 2002b; Vieira et al., 1991) . In addition, it reduces both the amount of IFN-c mRNA (Niiro et al., 1992) and IFN-c secretion (Salek-Ardakani et al., 2002b) in activated human PBMCs. Jochum et al. (2012) demonstrated that human PBMCs infected with EBV deleted for BCRF1 produced significantly higher levels of the proinflammatory cytokines IFN-c, IL-2, IL-6 and TNF-b, whereas levels of IL-1, IL-5, IL-8 and TNF-a were similar to those observed with the parental WT strain. Interestingly, these authors also observed an increased production of human IL-10 by PBMCs infected with the BCRF1-deleted strain. This observation suggests that vIL-10 could regulate human IL-10 expression. However, the observed effect could also have been an indirect consequence of the higher level of pro-inflammatory cytokines resulting from infection by the EBV vIL-10-deleted recombinant (Jochum et al., 2012) . Finally, Brodeur and Spencer (2010) demonstrated that anti-human IL-10 antibodies bind to and neutralize the immunosuppressive activity of EBV vIL-10, but not HCMV cmvIL-10. This observation is consistent with the higher homology existing between EBV vIL-10 and human IL-10 (92.3 % identity) compared with HCMV cmvIL-10/human .
The inhibition of cytokine activities was also demonstrated for two viruses infecting sheep (OvHV-2 and ORFV) using different in vitro systems. OvHV-2 vIL-10 inhibited IL-8 production by LPS-stimulated ovine macrophages (Jayawardane et al., 2008) , whereas ORFV vIL-10 inhibited TNF-a and IL-8 production from LPS-stimulated ovine macrophages and ionophore/phorbol myristate acetatestimulated keratinocytes, as well as IFN-c and GM-CSF production by concanavalin-A-stimulated PBMCs (Haig et al., 2002a, b) . However, ORFV vIL-10-knockout virus showed no effect on infected keratinocyte IL-8 and TNF-a production (Haig et al., 2002b) . ORFV vIL-10 has also been shown to inhibit expression and secretion of TNF-a in LPS-activated mouse peritoneal macrophages (Imlach et al., 2002) , to inhibit TNF-a and IL-1b in the human monocyte cell line THP-1 activated by LPS (Imlach et al., 2002; Wise et al., 2007) , and to inhibit production of IL-8, IL-1b and TNF-a in LPS-stimulated ovine alveolar macrophages (Fleming et al., 2000) . Furthermore, inhibition of IFN-c production in PBMCs by ORFV vIL-10 was demonstrated (Fleming et al., 2000) . Compared with human IL-10, ORFV vIL-10 possesses reduced ability to impair THP-1 monocyte proliferation in the presence of LPS (Wise et al., 2007) . However, it would be interesting to compare the biological activities of ORFV vIL-10 to those of ovine IL-10.
Deregulation of MHC and co-stimulatory molecule expression. Studies of the vIL-10s encoded by HCMV and EBV have demonstrated their ability to deregulate MHC and costimulatory molecule expression. HCMV cmvIL-10 and RhCMV vIL-10 reduced cell surface expression of classical MHC class I and II molecules (Jaworowski et al., 2009; Jenkins et al., 2008b; Raftery et al., 2004; Spencer et al., 2002) , but also increased expression of the non-classical MHC molecules HLA-DM and HLA-G on LPS-stimulated human MDDCs and monocytes, respectively (Raftery et al., 2004; Spencer et al., 2002) . These observations suggest that HCMV cmvIL-10 could prevent antigen presentation to T-cells through MHC class I molecule downregulation, but could simultaneously protect MHC class I-negative cells from NK-cell-mediated lysis through upregulation of HLA-G (Rouas-Freiss et al., 1997) . Although independent studies demonstrated the inhibitory effect of HCMV cmvIL-10 on MHC class I expression in different LPS-stimulated cell types, Pepperl-Klindworth et al. (2006) suggested that HCMV cmvIL-10 secreted during the productive phase of HCMV infection has no direct impact on MHC class I-restricted antigen presentation on non-infected bystander cells in the context of viral infection (Pepperl-Klindworth et al., 2006) . HCMV cmvIL-10 has also been shown to inhibit LPS-induced enhancement of co-stimulatory molecules (CD40, CD80, CD86, B7-H1 and B7-DC) on the surface of MDDCs (Jenkins et al., 2008b; Raftery et al., 2004) . LAcmvIL-10 reduces the expression of MHC class II molecules, but, in contrast to cmvIL-10, does not downregulate expression of MHC class I molecules and co-stimulatory molecules (CD40, CD80 and CD86) on LPS-stimulated MDDCs (Jenkins et al., 2008b) . The reduction of cell surface MHC class II molecule expression by LAcmvIL-10 was comparable to the effect of cmvIL-10 on both immature myeloid progenitor cells and human monocytes (Jaworowski et al., 2009; Jenkins et al., 2008b) . Jenkins et al. (2008b) suggested a possible mechanism for the reduction of MHC class II cell surface expression at the level of the transcriptional activity of CIITA, a gene that encodes a protein regulating the transcription of genes involved in the MHC class II biosynthesis pathway. The authors demonstrated that cmvIL-10, as well as LAcmvIL-10, significantly inhibited transcription of CIITA, and that this resulted in downregulation of expression of HLA-DR a, b and invariant chain. In addition, both cmvIL-10 and LAcmvIL-10 may inhibit MHC class II surface expression acting at the posttranslational level by blocking transport of MHC class II molecules to the cell surface (Jenkins et al., 2008b) . In addition to the above-mentioned functional studies utilizing recombinant LAcmvIL-10, Cheung et al. (2009) demonstrated that CD34 + myeloid progenitor cells infected latently by an HCMV strain deleted for the UL111A gene expressed a higher level of surface MHC class II molecules compared with cells infected with the parental strain. Cells infected with the knockout strain became recognizable by allogeneic and autologous CD4 + T-cells (Cheung et al., 2009) . EBV vIL-10 was shown to reduce both constitutive and IFN-c-or IL-4-induced MHC class II cell surface expression on monocytes and macrophages (de Waal Malefyt et al., 1991b; Salek-Ardakani et al., 2002a, b) . This resulted in a decrease of antigen presentation by monocytes and, as a consequence, a reduction of T-cell proliferation (de Waal Malefyt et al., 1991b) . EBV vIL-10 also inhibited the expression of intercellular adhesion molecule ICAM-1 and co-stimulatory molecules (CD80 and CD86) on monocytes and macrophages when added simultaneously with IFN-c (Salek-Ardakani et al., 2002a) . Interestingly, EBV vIL-10 inhibited IFN-c-induced MHC class I expression on monocytes and macrophages only when it was added 2 h prior to the addition of IFN-c, suggesting that it affects an early step in the IFN-c signalling pathway (Salek-Ardakani et al., 2002a) .
Inhibition of DCs. DCs play key roles in immune responses. vIL-10s have been shown to affect their maturation, functionality and survival. HCMV cmvIL-10 inhibited LPS-induced pro-inflammatory cytokine production by immature DCs (Chang et al., 2004; Raftery et al., 2008) , but was also shown to have pronounced long-term effects on mature DCs. Although it enhanced the migration of mature DCs towards peripheral lymph nodes, it also reduced their production of cytokine (Chang et al., 2004) . In addition, the inability of mature DCs to secrete IL-12 was maintained, even when they were restimulated by the activated T-cell signal CD40 ligand in the absence of cmvIL-10. Finally, cmvIL-10 induced endogenous cIL-10 expression in DCs, further increasing its modulatory effects (Chang et al., 2004) . Raftery et al. (2004) demonstrated that HCMV cmvIL-10, in contrast to EBV vIL-10, had additional effects on DCs that could affect negatively their roles in immunity. (i) It inhibited cell surface expression of molecules involved in antigen presentation, co-stimulation and adhesion. (ii) It increased apoptosis of LPS-stimulated immature DCs by blocking expression of the anti-apoptotic, long-form cellular FLIP protein. (iii) It induced a strong activation of STAT3 (a key mediator in cIL-10 transduction signal) in immature DCs. (iv) It upregulated expression of DC-SIGN and indolamine 2,3-dioxygenase (IDO) on LPS-stimulated immature DCs (Raftery et al., 2004) . DC-SIGN has been shown to play a role in DC infection with primary HCMV isolates (Halary et al., 2002) , whereas synthesis of IDO by human DCs caused suppression of T-cell responses (Hwu et al., 2000) . In contrast to HCMV cmvIL-10, LAcmvIL-10 showed no inhibitory effect in LPS-stimulated immature DCs on the expression of pro-inflammatory cytokines, costimulatory molecules and the maturation marker CD83 (Jenkins et al., 2008b) . However, using a recombinant virus deleted for the UL111A gene region, Avdic et al. (2011) demonstrated that HCMV vIL-10 expressed during latency inhibits differentiation of latently infected myeloid progenitor cells towards a DC phenotype, suggesting that LAcmvIL-10 may inhibit infected myeloid progenitors to differentiate into DCs, thereby limiting the presentation of latency-associated viral peptides by DCs (Avdic et al., 2011) . Immature DCs exposed simultaneously to LPS and ORFV vIL-10 showed enhanced ovalbumin-FITC uptake and reduced IL-12 expression, indicating inhibition of maturation of DCs. Furthermore, ORFV vIL-10 inhibited the upregulation of DC cell surface markers of activation and maturation such as MHC class II, CD80, CD83 and CD86, and inhibited the capacity of DCs to activate CD4 + T-cells (Chan et al., 2006) . Similarly, ORFV vIL-10 inhibited maturation and expression of MHC class II, CD80 and CD86 in stimulated murine bone marrow-derived DCs, and reduced their ability to present antigens (Lateef et al., 2003) .
Other immunosuppressive properties. In addition to the main immunosuppressive properties described above, some studies suggest potential additional immunosuppressive effects for some vIL-10s. HCMV cmvIL-10 decreased matrix metalloproteinase activity and deregulated cell-cell or cell-matrix interactions of infected cytotrophoblasts and endothelial cells (Yamamoto-Tabata et al., 2004) . EBV vIL-10 has been shown to impair some of the defence mechanisms of activated monocytes and macrophages. It inhibited production of the superoxide anion by PBMCs and monocytes (Niiro et al., 1992) , and prostaglandin E2 expression by LPS-stimulated monocytes (Niiro et al., 1994) . Furthermore, EBV vIL-10 inhibited NK/NKT-cellmediated lysis of infected B-cells through a direct effect on these cytotoxic cells and also through an indirect inhibitory effect on the CD4 + T-cells that contribute to the microenvironment required for NK/NKT cytotoxicity (Jochum et al., 2012) . Immunostimulatory properties. In addition to their immunosuppressive effects, some vIL-10s have retained at least some of the immunostimulatory properties of their cellular orthologues. HCMV cmvIL-10, but not LAcmvIL-10, showed a strong stimulatory effect on proliferation of the human B-cell lymphoma Daudi cell line and induced the production of human IL-10 (which is a growth factor for B lymphocytes) (Jaworowski et al., 2009; Spencer et al., 2008) . Jaworowski et al. (2009) studied the effect of cmvIL-10 and LAcmvIL-10 on monocytes. They demonstrated that cmvIL-10, but not LAcmvIL-10, increased the expression of Fcc receptors CD32 and CD64, as well as Fcc-receptor-mediated phagocytosis (Jaworowski et al., 2009) . RhCMV vIL-10 has been shown to stimulate proliferation of TF-1/IL-10R1 cells, which are human erythroleukaemic cells proliferating upon addition of human IL-10 to the media (Logsdon et al., 2011) .
EBV vIL-10 has also been shown to stimulate proliferation and differentiation of human B-cells as well as immunoglobulin production (Defrance et al., 1992; Rousset et al., 1992; Stuart et al., 1995) . However, EBV vIL-10 lacks several of the other immunostimulatory functions expressed by cIL-10, such as co-stimulation of mouse thymocyte proliferation, mast cell proliferation and upregulation of MHC class II expression on B-cells (Vieira et al., 1991) .
The ability of the OvHV-2 and ORFV vIL-10s to stimulate cell proliferation to levels comparable to those obtained with ovine IL-10 has been demonstrated by independent studies. OvHV-2 vIL-10 induced proliferation of murine mast cell line D-36 in conjunction with IL-4 (Jayawardane et al., 2008) . ORFV vIL-10 has been shown to induce proliferation of murine thymocytes in the presence of IL-2 (Fleming et al., 1997) , ovine mast cells stimulated with IL-3, a murine mast cell line D-36 stimulated with IL-4 (Haig et al., 2002b) and murine MC/9 mast cells stimulated with IL-3 and IL-4 (Imlach et al., 2002) .
Biological activities of vIL-10s determined in vivo. Numerous molecular and in vitro studies suggest that, following capture, there has been adaptive evolution of vIL-10 through positive selection to retain the properties most beneficial for the viral life cycle. However, very few studies have addressed the role of vIL-10 in vivo by comparison of a WT strain and derived deleted and revertant strains. This approach, which is essential for drawing conclusions on biological relevance in vivo, has been followed for only three viruses: RhCMV, ORFV and CyHV-3. Chang and Barry (2010) demonstrated that RhCMV vIL-10 has various effects on both the innate and adaptive immune responses against RhCMV in infected rhesus macaques. They performed comparative infections with a WT strain and a derived recombinant strain deleted for UL111A. Skin biopsies from macaques infected with the deleted strain exhibited a higher level of cellularity at the site of infection, but contained a lower frequency of CD68 + macrophages. The latter observation suggests that RhCMV vIL-10 could contribute to the recruitment of permissive cells on viral replication sites. RhCMV vIL-10 was also shown to reduce trafficking of myeloid DCs to draining lymph nodes and to decrease priming of naïve CD4 + T-cells (Chang & Barry, 2010) . Although RhCMV vIL-10 has no effect on IgM production, it inhibited B-cell differentiation and antibody isotype switching, resulting in a permanent deficit of circulating anti-RhCMV IgG. In addition, RhCMV vIL-10 delayed antibody maturation and attenuated the magnitude of antiviral antibody titre (Chang & Barry, 2010) . Finally, it was also shown to reduce the frequency of RhCMV-specific effector T-helper cells secreting IFN-c or IL-2, and T-cell proliferation (Chang & Barry, 2010) .
The activity of vIL-10 encoded by ORFV in vivo has been analysed in its natural host, i.e. sheep. A preliminary study revealed that the frequency of IFN-c mRNA-expressing cells in skin lesions was higher in animals infected with the vIL-10-knockout virus than in animals infected with the parental WT virus (Fleming et al., 2000) . Interestingly, after primary infection, smaller, less-severe lesions were observed in animals infected with the vIL-10-knockout virus than those observed in animals infected with the WT parental or revertant strains .
Recently, the role of CyHV-3 vIL-10 was studied in vivo using an artificial zebrafish embryo model (Sunarto et al., 2012) . It was shown that injection of CyHV-3 ORF134 mRNA into zebrafish embryos increased the number of lysozyme-positive cells to a degree similar to that of zebrafish IL-10 mRNA (Sunarto et al., 2012) . However, Ouyang et al. (2013) demonstrated that CyHV-3 vIL-10 does not significantly affect its virulence in common carp or the host innate immune response. Thus, infection of carp with ORF134-deleted, ORF134-revertant or WT strains induced comparable levels of CyHV-3 disease (Ouyang et al., 2013) . Moreover, quantification of viral load and real-time PCR investigating the expression of several carp inflammatory cytokines at various times postinfection did not reveal any significant differences between groups of fish infected with the three viral genotypes (Ouyang et al., 2013) . Similarly, histological examination of the gills and kidneys of infected fish revealed no significant differences between fish infected with the ORF134-deleted virus and those infected with the control parental or revertant strains (Ouyang et al., 2013) . Taken together, the results demonstrated that CyHV-3 vIL-10 is essential for neither viral replication in vitro nor virulence in common carp.
vIL-10s as a topic of applied research
In addition to their importance in fundamental research, a large number of studies demonstrate a role for vIL-10s in applied research. A thorough description of this abundant literature is beyond the scope of this review. Here, we P. Ouyang and others describe briefly the two main types of applied research developed on vIL-10s. These studies investigate the potential of vIL-10s as candidate antigens or target genes (production of attenuated recombinant vaccines) for the development of antiviral vaccines, or as immunosuppressive agents to prevent immunopathologies.
For vIL-10s that alter innate or adaptive immunity in vivo, vaccine-mediated neutralization of their function could contribute to inhibition of the establishment of a persistent infection in naïve subjects or even interrupt a pre-existing persistent infection. This theoretical possibility could apply to most vIL-10s that are quite divergent in sequence from the host IL-10. To address this concept using the RhCMV model (Yue & Barry, 2008) , inactive RhCMV vIL-10 mutants were designed as antigen candidates and shown to induce the production of neutralizing antibodies specific to vIL-10 (not cross-reacting with host IL-10) (de Lemos Rieper et al., 2011; Logsdon et al., 2011) . The ability of such an antigen candidate to interfere with persistent RhCMV infection (establishment or maintenance) has not yet been tested. However, a recent study on the immunogenicity of vIL-10 in RhCMV-infected rhesus macaques demonstrated that the serum of persistently infected animals contained high levels of vIL-10-neutralizing antibodies (Eberhardt et al., 2012) . This observation suggests that vIL-10-based vaccines may not be able to interrupt an established persistent infection. Interestingly, development of antibodies against RhCMV vIL-10 in uninfected rhesus macaques immunized with plasmid vectors encoding engineered, non-functional RhCMV vIL-10 variants resulted in reduction of RhCMV replication at the inoculation site and RhCMV shedding in bodily fluids during subcutaneous RhCMV challenge (Eberhardt et al., 2013) . Alternatively, for vIL-10s playing a significant role in virulence, deleted recombinant strains could be produced as attenuated vaccines, as suggested for RhCMV (Chang & Barry, 2010) .
The data presented in the previous section collectively indicate that vIL-10s, compared with cIL-10, have a restricted bioactivity profile favouring immunosuppressive activities. Based on this profile, several independent groups have suggested exploiting vIL-10s as potential immunosuppressive agents. Studies performed in laboratory animal models support this concept. Researchers have demonstrated the potential of some vIL-10s to induce localized immunosuppression in order to favour long-term engraftment of transplanted tissues (EBV vIL-10) (Nast et al., 1997; Qin et al., 1996) , reduce the host's foreign-body reaction against implanted biomaterials (HCMV cmvIL-10) (van Putten et al., 2009) or treat collagen-induced arthritis (EBV vIL-10) (Keravala et al., 2006; Kim et al., 2000; Lechman et al., 1999; Ma et al., 1998; Whalen et al., 1999) .
Concluding remarks
Most viruses have been co-evolving with their hosts for millions of years. During this process, viruses and hosts have been acting as strong sources of selection pressure on each other. Thus, viruses have been constantly selecting individuals among the host population that have the most efficient immune systems, while the continual improvement of the immune system has been selecting viruses that have evolved strategies to control the host immune response. Fundamental studies in immunology have demonstrated the key roles of cIL-10 in the immune system. The various independent acquisitions of IL-10 orthologues by viruses belonging to different viral genera, subfamilies and even families further support the importance of cIL-10 in the immune system. After their capture by the viral genome, cellular sequences evolve through positive selection to retain properties that are the most beneficial for the virus and, sometimes, to acquire novel properties. The vIL-10s illustrate this concept. In comparison with their cellular orthologues, vIL-10s have evolved towards a more restricted bioactivity profile consisting mainly, but not exclusively, of immunosuppressive activities. Interestingly, studies on HCMV cmvIL-10 and LAcmvIL-10 demonstrate that evolution of a captured IL-10 gene in the viral genome has led to the expression of two different transcripts that have specific biological activities adapted to the replication and latent phases.
